MUNICH, Germany -- Infineon Technologies, the world s sixth-largest semiconductor company, is the first semiconductor manufacturer to join the Global Business Coalition on HIV/AIDS (GBC). The coalition, founded in 1997 and based in New York, is committed to increasing the role of business in supporting international ef
BASKING RIDGE, NJ - Millennium Biotechnologies, Inc. a wholly owned subsidiary of Millennium Biotechnologies Group, Inc. announces effective December 22, 2003 Resurgex Plus(TM), formally known as Prosurgex(TM), has been included for expanded nutritional supplementation reimbursement based on the recommendations of the
BETHLEHEM, Pa. -- OraSure Technologies, Inc., the market leader in oral fluid diagnostics, announced today that it has submitted the additional data requested by the U.S. Food and Drug Administration ( FDA ) in support of an HIV-2 claim for its OraQuick(R) Rapid HIV-1 Antibody Test. In June 2003, the Company submitte
PALO ALTO, Calif. - Frost & Sullivan, a leader in growth consulting, today named Retractable Technologies Inc., which manufactures and markets the VanishPoint(R) line of automated retraction safety needle devices, as the recipient of its 2003 Product Quality Leadership Award. In announcing the award, Frost & Su
PORTLAND, Ore.-- A matching grant of $450,000 has been awarded to Cascade AIDS Project (CAP) to fund their innovative Kids Connection program for children whose parent or caretaker is HIV-positive. Of 313 nationwide applications to the highly competitive Local Initiative Funding Partners program of The Robert Wood John
NEW YORK-- Strategic Simulation provided an unprecedented forum for the generation of ideas on accelerating the business response to HIV/ AIDS in New Delhi, India The Global Business Coalition on HIV/AIDS, Booz Allen Hamilton and the Confederation of Indian Industry issued a groundbreaking report today detailing the fi
OAKLAND, Calif.--Kaiser Permanente has awarded Healthy Community Grants totaling $195,000 to 36 agencies in Northern California that provide special services to people who are HIV-positive or have acquired immune deficiency syndrome (AIDS). Kaiser Permanente has now given $3.1 million in grants to organizations serving
SAN FRANCISCO -- The Pangaea Global AIDS Foundation, the international arm of the San Francisco AIDS Foundation, today applauded the South African government s landmark decision to integrate HIV antiretroviral drugs (ARVs) into its HIV care response, an action that included the direct involvement of Pangaea s staff. Ov
WASHINGTON -- Univision Communications Inc. (NYSE: UVN), the leading Spanish-language media company in the United States , today announced the official launch of its integrated cross-platform health education initiative Salud es Vida...Enterate! . The mission of this initiative is to promote healthy lifestyles and enco
WHITEHOUSE STATION, N.J.-- Merck & Co. , Inc. today launched the Merck Vaccine Network - Africa , an initiative designed to contribute to improving the immunization infrastructure in Africa. The multi-year program will fund the establishment of a network of vaccination training centers at academic institutions in
BETHLEHEM, Pa.-- OraSure Technologies, Inc., the market leader in oral fluid diagnostics, announced today that it will be submitting a small amount of additional data to the U.S. Food and Drug Administration ( FDA ) in support of an HIV-2 claim for its OraQuick(R) Rapid HIV-1 Antibody Test. In June 2003, the Compan
MEMPHIS, Tenn.-- FedEx Express, a subsidiary of FedEx Corp., transported more than 88,000 pounds of concert equipment in support of Nelson Mandela s global AIDS awareness and fundraising campaign, 46664 - Give 1 Minute Of Your Life to AIDS. The company donated the use of its extensive global transportation network and
LAS VEGAS-- Samaritan Pharmaceuticals Inc.: -- Presentation to Focus on Positive Phase II Results for HIV Immuno-Modulator with Antiviral Properties -- One-on-One Meetings Scheduled with Over Twenty Pharmaceutical Companies Samaritan Pharmaceuticals Inc. and Samaritan Research Labs, Georgetown University, announced tod
DALLAS-- Through the generous contributions of the Meadows Foundation, VHA Inc. and others, AIDS Arms, Inc., the largest Dallas-based nonprofit agency providing both outpatient medical care and social service case management programs for persons diagnosed with HIV/AIDS, announced today the purchase of the building for
LOS ANGELES--The European Patent Office has approved the first of four pending patents licensed to CytoDyn, Inc. The new European patent covers the use of Cytolin to treat HIV/AIDS and is equivalent to U.S. Patent No. 5,424,066, one of three U.S. patents licensed to CytoDyn by scientist Allen D. Allen, who serves as Cy
BETHLEHEM, Pa.-- OraQuick(R) to be Featured in December 2003 Issue as Winner in Personal Health Category OraSure Technologies, Inc., the market leader in oral fluid diagnostics, announced today that its OraQuick(R) Rapid HIV-1 Antibody Test has been awarded a 2003 Best of What s New award by Popular Science magazine in
COLUMBUS, Ohio --E Med Future, Inc., manufacturer of NeedleZap(R), a medical device that disintegrates used hypodermic needles, announced today that their exclusive sales and marketing partner, American Health & Safety Products, Inc. (AHSP), has secured an agreement with National Distribution & Contracting, Inc
NEW YORK -- Actors, writers and producers of dramatic TV series broadcast around the world will be joined by international business, media and public health leaders in New York November 18 to set the course for one of the most innovative and potentially powerful HIV/AIDS initiatives. Organized by Columbia University s
PHILADELPHIA--Hemispherx Biopharma, Inc. announced today that the Company will be giving a presentation of new in vitro data on Alferon N(R) as a potent inhibitor of SARS coronavirus at the 14th International Antiviral Symposium and Workshop on Sunday, November 9, 2003 at 4:15 p.m. in Antalya, Turkey . D
BASKING RIDGE, N.J.--Millennium Biotechnologies, Inc., a wholly owned subsidiary of Millennium Biotechnologies Group, Inc., announces a 172% increase in unit sales over the preceding quarter along with important initial clinical trial results. With access to New York Medicaid, the largest Medicaid reimbursed market in
PHILADELPHIA-- Growing Recognition for Potential of Ampligen Attracts Discoverer of HIV/AIDS Virus & Pioneer in Disease Treatment and Prevention Hemispherx Biopharma, Inc. announced today the appointment of Dr. Luc Montagnier to its Scientific Advisory Board. Dr. Montagnier, who discovered the AIDS virus in 1983, t
FOSTER CITY, Calif.-- Gilead Sciences , Inc. today announced that the European Commission has granted Marketing Authorisation for Emtriva(TM) (emtricitabine, 200 mg hard capsules and 10 mg/mL oral solution) in all 15 member states of the European Union. On July 24, 2003 the Committee for Proprietary Medicinal Products
WARSAW, Poland-- Gilead Sciences , Inc. today announced data from two studies evaluating the safety and tolerability of its once-daily antiretroviral agent Viread (R) (tenofovir disoproxil fumarate). These data will be presented this week at the 9th Conference of the European AIDS Clinical Society in W
BOSTON-- Data Presented at 54th Annual Meeting of the American Association for the Study of Liver Diseases Gilead Sciences today announced that treatment with its once-daily, oral antiviral agent Hepsera(R) (adefovir dipivoxil 10 mg) was associated with sustained reductions in levels of
LAS VEGAS-- Samaritan Pharmaceuticals Inc. -- Proof of Concept (Phase I/II Clinical Study Report) Submitted to FDA -- Phase III Study Design Being Prepared to Submit to FDA for End of Phase II Meeting -- Newly Identified Second HIV Drug Being IND Readied to Submit to FDA Samaritan Pharmaceuticals Inc. and Samaritan
CAMBRIDGE, Mass. & MONTREAL--Dyax Corp. and privately held URRMA Biopharma Inc. announced today that they have entered into an agreement for the discovery and development of fully human monoclonal antibodies to the R7V antigen, a specific epitope found on all types and clades of the human immunodeficiency virus (HI
LA JOLLA, Calif.--Aethlon Medical, Inc. announced today that Jean-Claude Chermann, Ph.D., has joined its Science Advisory Board. Dr. Chermann is a pioneer in the study of retroviruses, and was the principal investigator of the research team that collaborated in the first isolation and characterization of HIV (The AIDS
NEW YORK -- The Asia Society yesterday launched its AIDS in Asia initiative funded by the Bill & Melinda Gates Foundation, to raise awareness and help combat a looming Asian HIV/AIDS pandemic. The inaugural event was a videoconference between New York and New Delhi featuring 20 emerging leaders in India s fight aga
WATERTOWN, Mass.--Pathfinder International announced today that it will be featured in the 10th season of The Visionaries, an award-winning public television series that profiles nonprofit organizations working to bring about positive social change. The program is hosted by acclaimed actor Sam Waterston of Law & Or
NEW DELHI, INDIA -- Public/private partnerships have a critical role to play in the fight against the HIV/AIDS epidemic in India , according to the results of a process that simulates various factors in the development of the disease and society s reaction to it. This was one of the most important findings of an unprec
TARRYTOWN, N.Y.-- Progenics Pharmaceuticals, Inc. today announced that the investigational drug methylnaltrexone (MNTX) relieved opioid-induced urinary retention in a phase 2 clinical trial. Inability to urinate is particularly prevalent in men receiving opioid pain therapy after surgery and may require the insertion o
DURHAM, N.C.-- Trimeris, Inc. today announced an interim update on the launch of FUZEON (enfuvirtide) and initiatives put in place by Roche and Trimeris to ensure the long-term success of this important new medicine. Drug shipments of FUZEON, the first HIV fusion inhibitor and first injectable HIV medication, to U.S. p
GABORONE, Botswana-- Experts working on the front lines to fight HIV/AIDS in one of the world s hardest hit places -- the African country of Botswana -- will report on recent progress in that country s national response to the epidemic during a satellite symposium Monday, Sept. 22 at the 13th International Conference o
SEATTLE & WHITEHOUSE STATION, N.J.-- Public/private partnership of Merck and the HIV Vaccine Trials Network brings collective strengths to bear on global problem of HIV/AIDS The HIV Vaccine Trials Network (HVTN) and Merck & Co. , Inc. today announced that they have begun the first global clinical trial of Merck
LYON, France & WHITEHOUSE STATION, N.J.-- Aventis and Merck & Co. , Inc. today announced that human trials have begun to test the safety and immune responses generated by using a combination of two anti-HIV-1 vaccine candidates in a complementary way. The collaborative Phase I study looks at a prime-boost r
BETHLEHEM, Pa.--OraSure Technologies, Inc., the market leader in oral fluid diagnostics, announced today that the use of its OraQuick(R) Rapid HIV-1 Antibody Test at the point of care was found to provide testing results four-times faster than when the OraQuick(R) test was used in a laboratory setting. These findings r
LAS VEGAS--Samaritan Pharmaceuticals Inc., its philanthropic arm, the Samaritan Innovative Science Foundation (SISF), and A Harvest Biotech Foundation International, Africa (AHBFI) today announced the formation of a collaboration to provide free drugs to children with AIDS in Africa. Why It Matters UNICEF noted that wh
BETHLEHEM, Pa.--OraSure Technologies, Inc., the market leader in oral fluid diagnostics, today announced that it plans to publicly offer 5,000,000 shares of its common stock. The offering will be made pursuant to a registration statement covering shares of common stock that became effective on August 8, 2003. The Compa
BETHLEHEM, Pa.-- OraSure Technologies, Inc., the market leader in oral fluid diagnostics, announced today that its OraQuick(R) Rapid HIV-1 Antibody Test has been approved by the U.S. Food and Drug Administration ( FDA ) for use in detecting HIV-1 antibodies in venipuncture whole blood specimens. This is the second
LAS VEGAS--Samaritan Pharmaceuticals Inc.: Samaritan Innovative Science Foundation (SISF) key initiatives are to: -- Provide Free Life Saving Drugs to Children of the World with AIDS -- Create Innovative Traveling BIO-BUS DNA Discovery Lab to Enhance the Scientific Interests of Teenagers and Children -- To Support
STANFORD, Calif.--Researchers at the Stanford University School of Medicine have found in laboratory experiments a potentially novel way to prevent HIV infections in women. They ve discovered that bacteria that naturally live in the body can be genetically enhanced for potent antiviral activity. Modifications to this u
WASHINGTON--The HIV/AIDS epidemic continues to be one of the chief health crises in communities of color, among African Americans, Hispanics, Asian Pacific Islanders and Native Americans, who account for the majority of people living with HIV and AIDS in the United States and its territories. Research studies and curre
WILMINGTON, Del. & ATLANTA--Incyte Corporation and Pharmasset, Ltd. announced today that they have entered into a collaborative licensing agreement to develop and commercialize the antiretroviral drug Reverset(TM), also known as RVT, D-D4FC or DPC-817, which is currently in Phase IIa clinical development for the tr
PASADENA, Calif.--Kaiser Permanente s Educational Theatre Programs (ETP), the largest professional educational theatre touring company in the country, kicked off its new Southern California season yesterday (Tuesday) by bringing back the pain of adolescence to three hundred physicians. ETP s Nightmare on Puberty Street
WASHINGTON -- The National Minority AIDS Council (NMAC) today announced its speakers and plenary session agendas for the 2003 U.S. Conference on AIDS (USCA), to be held in New Orleans, Louisiana, September 18th through the 21st. NMAC is the largest national organization dedicated to addressing the challenges of HIV/AID
BOUNTIFUL, Utah-- Specialized Health Products International, Inc. today announced that SHPI has entered into a worldwide license agreement with BD (Becton, Dickinson and Company) relating to the manufacture and marketing of safety-engineered spinal and epidural needles and certain other specialty needles sold by BD. Pr
HOUSTON-- CytoGenix Inc. announced Tuesday that Phanuel Pursuits, LLC (USVI) has exercised its option for an exclusive license for the manufacture and distribution of CytoGenix proprietary anti-herpes topical cream in the People s Republic of China and also obtained an additional option for a similar arrangement for
CARLSBAD, Calif.--The Immune Response Corporation today announced the appointment of Paul Volberding, M.D. to its Scientific Advisory Board. Dr. Volberding, one of the foremost experts on HIV/AIDS, is professor and vice chair of the Department of Medicine at the University of California, San Francisco (UCSF) and princi
FOSTER CITY, Calif.-- Gilead Sciences today announced that the company has initiated enrollment in Study 934. This Phase III study is designed to assess the efficacy of a once-daily regimen containing Viread (R) (tenofovir disoproxil fumarate) and Emtriva(TM) (emtricitabine) in combination with
WASHINGTON -- The National Minority AIDS Council (NMAC) today announced its partners and program sessions for the 2003 U.S. Conference on AIDS (USCA), to be held in New Orleans, Louisiana, September 18th through the 21st. NMAC is the largest national organization dedicated to addressing the challenges of HIV/AIDS withi
PHILADELPHIA -- Hemispherx Biopharma, Inc., a leading company in the experimental-stage development of immune based therapies primarily addressing the diseases of Chronic Fatigue Syndrome, HIV/AIDS and HPV , announced today the receipt of major new patents in Europe on a set of orally active low molecular weight RNA co
FOSTER CITY, Calif. -- Gilead Sciences , Inc. announced today that it has entered into a non-exclusive licensing agreement with Chiron Corporation for the research, development and commercialization of small molecule therapeutics against selected hepatitis C virus (HCV) drug targets.
FOSTER CITY, Calif.-- Gilead Sciences , Inc. today announced that the company has entered into a licensing agreement with Japan Tobacco Inc. (JT) under which JT will commercialize products in Gilead s HIV portfolio in Japan. The agreement includes
FORT LEE, N.J.--Crimson Pharmaceutical ( Hong Kong ) Ltd, the parent company of Crimson Pharmatech USA, today announced an agreement to license three drug candidates from a California based company, Octamer Inc. The three licensed compounds are being investigated to treat a variety of diseases including cancer, AIDS, a
PHILADELPHIA -- Hemispherx Biopharma, Inc. announced today that at the 2nd IAS Conference on HIV Pathogenesis and Treatment in Paris, France , most recent data of its Phase IIb clinical trial, AMP 720, was reported. Using Strategic Treatment Interruption (STI), patients antiviral HAART regimens are interrupted and Ampl
HUDSON, Mass.-- Doctors in Uganda and Kenya , whom until now have been battling epidemics like AIDS with limited resources, are turning to new technology to give them the information they need to help save lives. AIDS afflicts 5.3 million people in the world, 3.8 million of whom live in sub-Saharan Africa.
PLEASANTON, Calif.-- Polycom, Inc., the world s leader in video and voice conferencing, conference bridges and integrated web collaboration solutions, today announced that its industry-leading video conferencing systems and conference bridges will join together world leaders in the upcoming African Union Summit s Speci
CARLSBAD, Calif. & CAMBRIDGE, Mass.-- The Immune Response Corporation (Nasdaq:IMNR) and Hybridon, Inc. today announced that The Immune Response Corporation is conducting preclinical studies to evaluate a potential 2nd generation HIV vaccine. The 2nd generation vaccine would be based on The Immune Response Corporati
FOSTER CITY, Calif.--(BUSINESS WIRE)--July 2, 2003-- Gilead s Second HIV Therapeutic and Third Antiviral Approved in Two Years Gilead Sciences today announced that the U.S. Food and Drug Administration ( FDA ) has cleared for marketing Emtriva(TM) (emtricitabine), a new 200 mg one-capsule, once-daily nucleoside reverse
ALAMEDA, Calif.--Calypte Biomedical Corporation: -- Dr. George, former Senior VP of Infectious Disease Research and Development at OraSure Technologies, Inc., and a 30-Plus Year Veteran of the Centers for Disease Control and Prevention -- Dr. Ronald Mink to Co-Lead Calypte s Rapid Business Calypte Biomedical Corporatio
NEWPORT BEACH, Calif.--Acacia Research Corporation announced today that CombiMatrix is collaborating with the research group of Dr. Bonaventura Clotet, M.D., Ph.D., of the Retrovirology Laboratory irsiCaixa, a leading research and treatment center for AIDS in Europe, to conduct the initial efficacy screening of pooled
ALAMEDA, Calif.--Calypte Biomedical Corporation, the developer and marketer of the only two FDA approved HIV-1 antibody tests that can be used on urine samples, as well as an FDA approved serum HIV-1 antibody Western blot supplemental test, today announced that effective immediately Nancy Katz will leave the company.
ALAMEDA, Calif.--Calypte Biomedical Corporation, the developer and marketer of the only two FDA approved HIV-1 antibody tests for use with urine samples, announced that it has received an additional order for Urine HIV-1 EIA tests from its Chinese distributor, Zhong Yang Pute Co. ( ZYPute ), a distributor of medical pr
CARLSBAD, Calif.-- Trial Designed to Evaluate Effect of REMUNE(R) on HIV-1 Specific Immunity in Antiretroviral Naive Subjects -- Patient Population Not Previously Studied by Company The Immune Response Corporation today announced that it has initiated preparations to launch a Phase II trial of REMUNE(R) in
ALAMEDA, Calif. & ABBOTT PARK, Ill. -- Distributed by Abbott Laboratories , System is Now Available on Platform Used by Nation s Largest Clinical Testing Laboratories Celera Diagnostics, a joint venture between the Applied Biosystems Group and Celera Genomics Group of Applera Corporation, and Abbott Laboratories to
ALAMEDA, Calif.--Calypte Biomedical Corporation, the developer and marketer of the only two FDA approved HIV-1 antibody tests for use with urine samples, announced that it has appointed Enfield Medical Co. Ltd. as its exclusive distributor for Taiwan . Enfield is a Taipei-based company,
BETHLEHEM, Pa.--OraSure Technologies, Inc., the market leader in oral fluid diagnostics, announced today that its OraQuick(R) Rapid HIV-1 Antibody Test will be donated to numerous locations across the United States to conduct free HIV testing in observance of National HIV Testing Day on June 27, 2003. This will mark th
MORRISTOWN, N.J.-- Medsn Inc.: Utilizing 2D and 3D Animation, Medsn Demonstrates Mechanism of Action and Complexity of Compound for a New HIV Drug to Support Product Launch Initiatives Designed for Sales Specialists, Marketing and Medical Affairs Personnel, MDs, RNs, and Other Healthcare Providers Medsn Inc., the premi
ALAMEDA, Calif.--Calypte Biomedical Corporation, the developer and marketer of the only two FDA approved HIV-1 antibody tests for use with urine samples, announced that it has received an initial order from Mistaire LLC for HIV-1 Urine EIA screening tests and Urine HIV-1 Western Blot supplemental tests for use within t
BOSTON--Boston s minority community-based organizations working in the field of HIV/AIDS prevention now have new ammunition in their fight against the epidemic. The National Minority AIDS Council (NMAC), the nation s largest organization working with communities of color in the war against HIV/AIDS, will host a KIC (Kn
SAN DIEGO-- Data From South African Trial Presented at National Conference on Antimicrobial Resistance Hollis-Eden Pharmaceuticals, Inc. today announced additional data from a Phase II clinical trial conducted in South Africa in late-stage HIV patients who have progressed to AIDS (average starting CD4 count for patient
LOS ANGELES-- Members of the U.S. Congressional Black, Latino and Asian Pacific American Caucuses today convened in Los Angeles to join health and community leaders in a lively discussion on actions to take to reduce and eliminate racial and ethnic health disparities that are pervasive in underserved communities of col
MELBOURNE, Australia-- Norwood Abbey Ltd. announced that Australian research on rejuvenating the immune system, which could significantly help HIV/AIDS patients, has been seized upon by a team of distinguished international scientists for clinical trials. It is planned that up to 50 patients will undergo treatment in E
FARMINGDALE, N.Y.--Enzo Biochem,Inc., a leading biotechnology company specializing in genetic and immune regulation, announced today that the Office of Cellular, Tissue, and Gene Therapy of the U.S. Food and Drug Administration ( FDA ) released a clinical hold previously placed on Enzo s StealthVector(R) HGTV43 stem ce
ALAMEDA, Calif.--Calypte Biomedical Corporation, the developer and marketer of the only two FDA approved HIV-1 antibody tests that can be used on urine samples, as well as an FDA approved serum HIV-1 antibody Western blot supplemental test, announced that it has been informed by the Over the Counter Bulletin Board that
FOSTER CITY, Calif.-- Gilead Sciences , Inc. today announced that the European Commission has granted Marketing Authorisation to expand the indication of Viread (R) (tenofovir disoproxil fumarate) to include the product s use in antiretroviral-naive HIV infected patients in all 15 member states of the E
ALAMEDA, Calif.--Calypte Biomedical Corporation, the developer and marketer of the only two FDA approved HIV-1 antibody tests that can be used on urine samples, as well as an FDA approved serum HIV-1 antibody Western blot supplemental test, announced that it has received several recent FDA approvals for revisions to th
ALAMEDA, Calif.--Planned Parenthood Federation, the nation s largest voluntary reproductive health care organization, and Calypte Biomedical Corporation, the developer and marketer of the only two FDA-approved HIV-1 antibody tests that can be used on urine samples, as well as an FDA-approved serum HIV-1 antibody Wester
CARLSBAD, Calif.-- The Immune Response Corporation today announced the forthcoming publication of results from a trial involving REMUNE(R) by the peer-reviewed journal AIDS. The trial, while enrolling only a limited number of patients, concluded that vaccination with REMUNE(R) increased HIV-1 specific immune response i
BETHLEHEM, Pa.--OraSure Technologies, Inc., the market leader in oral fluid diagnostics, today announced the appointment of Ronny B. Lancaster to the Company s Board of Directors. Mr. Lancaster has extensive experience in the medical and public health fields, particularly in the development of public health policy and
WASHINGTON -- Bay Area minority community-based organizations (CBOs) working in the field of HIV/AIDS prevention will soon have new ammunition in their fight against the epidemic. The National Minority AIDS Council (NMAC), the nation s largest organization working with communities of color in the war against HIV/AIDS,
ALAMEDA, Calif.-- Calypte Biomedical Corporation today announced that the FDA has just authorized the use of its Cambridge Biotech HIV-1 Western Blot serum/plasma test as an additional specific test to be used with serum or plasma specimens obtained from subjects found to be reactive using rapid HIV-1 tests. This
WASHINGTON-- After receiving a kiss from President Bush on Tuesday, an HIV-positive Zambian mother is hoping for another expression of commitment from Congress: swift passage of the president s Emergency Plan for AIDS relief. World Vision representative Princess Kasune Zulu was among a small group of religious and busi
CARLSBAD, Calif.-- Company Taps University of Michigan s Gilbert S. Omenn, M.D., Ph.D., to Chair New Scientific Advisory Board, and Dorothy Bray, Ph.D., to Serve as Clinical Development Advisor The Immune Response Corporation today announced the creation of a Scientific Advisory Board to counsel the company in the deve
ALAMEDA, Calif.-- Johnson to Join Calypte s Board of Directors and to Actively Promote Awareness of Calypte s Urine-Based HIV Screening Test Today, the Magic Johnson Foundation, Inc. (http://www.magicjohnson.org) and Calypte Biomedical Corporation, in a joint effort, announced that Earvin Magic Johnson will join Calypt
SACRAMENTO, Calif.--Sean Harrigan, President of the California Public Employees Retirement System s Board of Administration issued the following statement today about news that GlaxoSmithKline is cutting the price of its combination AIDS drug Combivir : Glaxo should be commended for
LOS ANGELES--Amerimmune Pharmaceuticals, Inc. has suspended operations and petitioned for Chapter 7 bankruptcy after being served with two lawsuits. Following months of unsuccessful negotiations, one of the lawsuits was initiated by Los Angeles-based CytoDyn of New Mexico, Inc., the privately-held company from which Am
AUSTIN, Texas & OKLAHOMA CITY--Pure Protein L.L.C. has licensed three Hepatitis C transfected cell lines from the National Institutes of Health to use in a Hepatitis C vaccine discovery project. Pure Protein will use soluble HLA protein in its Proteome Expression Profiling (PEP) technology to discover virus-associa
MOUNTAIN VIEW, Calif.--Pathways Home, Hospice and Continuous Care (formerly MidPeninsula Pathways), the Bay Area s leading nonprofit provider of home care and hospice services, today announced the formation of a special Global Caring Project, a partnership with Pretoria Sungardens Hospice, located in
ALAMEDA, Calif.--Calypte Biomedical Corporation, the developer and marketer of the only two FDA approved HIV-1 antibody tests that can be used on urine samples, as well as an FDA approved serum HIV-1 antibody Western blot supplemental test, said today that its decision to establish a distribution relationship with Adal
LOS ANGELES--Vencor International, Inc., received a Letter of Intent from a major medical testing distribution company in Thailand today. The letter of intent provides the Thai company distribution rights for Vencor s HIV 1 & 2 Quick tests. Vencor management negotiated a minimum of 1,200,000 units will be ordered b
FOSTER CITY, Calif.--April 4, 2003-- Gilead Sciences today announced details of the Gilead Access Program, which will provide access to Viread (R) (tenofovir disoproxil fumarate), the company s once-a-day antiretroviral medication for HIV, at no profit in every country in Africa and in 15 additional co
ALAMEDA, Calif.--Calypte Biomedical Corporation, the developer and marketer of the only two FDA approved HIV-1 antibody tests for use with urine samples, announced that it has signed an exclusive three-year distribution agreement with Mistaire LLC to distribute the Company s Urine HIV-1 EIA and Western Blot test kits i
TORONTO--HIV-VAC, Inc announced today that Dr. Gordon Skinner, MD(Hons) the Director of Research of HIV-VAC and the original developer of HIV-VAC s proposed vaccine (NFU.Ac.HIV1RU1295(JM)) designed to combat HIV/AIDS, has, in conjunction with Intracell Vaccines Ltd, filed a patent application with the Unite
LYON, France & WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--March 27, 2003--A combination of two anti-HIV-1 vaccine candidates developed by Aventis Pasteur, a subsidiary of Aventis, and Merck & Co. , Inc., elicited levels of a cellular immune response against HIV-1 infection in monkeys that were higher than the l
SOUTH BURLINGTON, Vt.--Johnson & Perkinson is commencing today a class action in the U.S. District Court for the Northern District of California on behalf of purchasers of VaxGen , Inc. securities during the period between August 6, 2002 and February 26, 2003 (the Class Period ). The complaint charges VaxGen and
LOS ANGELES--AIDS Healthcare Foundation is deeply disappointed by today s announcement by Swiss pharmaceutical giant Roche which set pricing of Fuzeon, a promising new AIDS therapy, at just under $20,000 -- far out of reach of most HIV patients. Fuzeon is a new antiretroviral drug designed for HIV/AIDS patients who hav
MINNEAPOLIS-- Chronimed Inc. announced today that it has contracted with Roche to be the exclusive U.S. distributor of its new HIV medication, FUZEON(TM), as part of their U.S. Progressive Distribution Plan. FUZEON, jointly developed by Roche and Trimeris, Inc. received U.S. Food and Drug Administration (
ALAMEDA, Calif.--Calypte Biomedical Corporation, the developer and marketer of the only two FDA approved HIV-1 antibody tests that can be used on urine samples, as well as an FDA approved serum HIV-1 antibody Western blot supplemental test, announced today that the Harlem Congregations for Community Improvement plans t
LA JOLLA, Calif.--Aethlon Medical Inc. announced today that the United States Patent and Trademark Office (USPTO) has approved and issued patent #6528057 entitled: Method for removal of HIV and other viruses from blood. The patent, which is licensed exclusively to Aethlon Medical, addresses a method to remove viruses a
MONTREAL--Franc-Or Resources Corporation is pleased to announce that URRMA Biopharma Inc. ( URRMA ) has initiated its last study prior to the filing of a Premarket Approval (PMA) dossier with the US Food and Drug Administration ( FDA ) for the US commercialization of its Anti-R7V Diagnostic Kit. The study represents th
ALAMEDA, Calif.--Calypte Biomedical Corporation, the developer and marketer of the only two FDA-approved HIV-1 antibody tests that can be used on urine samples, today announced receipt of U.S. Food and Drug Administration (FDA) approval to eliminate the lot release testing requirement for the company s Cambridge Biotec
ALAMEDA, Calif.-- Calypte Biomedical Corporation, the developer and marketer of the only two FDA approved HIV-1 antibody tests that can be used on urine samples, as well as an FDA approved serum HIV-1 antibody Western blot supplemental test, announced today that the Harlem Congregations for Community Improvement will b
ALAMEDA, Calif.--Calypte Biomedical Corporation, the developer and marketer of the only two FDA approved HIV-1 antibody tests that can be used on urine samples, as well as an FDA approved serum HIV-1 antibody Western blot supplemental test, announced today that Planned Parenthood Golden Gate has added Calypte s urine H
LOS ANGELES-- Just three weeks after President Bush s groundbreaking State of the Union commitment to prevent seven million new HIV infections in Africa and the developing world and treat two million people with AIDS in poor countries with life-saving anti-retroviral therapy (ARV), California s VaxGen Corp
FOSTER CITY, Calif.-- Gilead Sciences , Inc. today announced that the European Union s Committee for Proprietary Medicinal Products (CPMP), the scientific committee of the European Medicines Evaluation Agency (EMEA), adopted a positive opinion to extend the indication of
CARLSBAD, Calif.--The Immune Response Corporation today announced that data suggests sustained HIV-specific immune response among patients involved with an extended Spanish Phase II clinical study (STIR-2102) of its therapeutic HIV vaccine REMUNE(R). The results of the study were presented Wednesday, February 12, 2003,
ALAMEDA, Calif.--Feb. 19, 2003--Calypte Biomedical Corporation, the developer and marketer of the only two FDA-approved HIV-1 antibody tests that can be used on urine samples, as well as an FDA-approved serum HIV-1 antibody Western Blot supplemental test, today announced that PathNet Esoteric Laboratory Institute has s
MENLO PARK, Calif.--Geron Corp. announced today the publication of a research study demonstrating the potential therapeutic benefit of activating telomerase in HIV-specific immune cells to increase their lifespan and to augment their antiviral activities. The data provide a rationale for telomerase activation in AIDS t
FORT LAUDERDALE, Fla.--The front-line fight against HIV/AIDS and Hepatitis C (HCV), two of South Florida s most widespread and deadly viral infections, has advanced another step. Wellness Center of South Florida and Hep-C ALERT, two established local non-profits, have joined to form the Coinfection Connection, a collab
NORTH MIAMI, Fla.--HIV and Hepatitis C (HCV) viruses have gained an even more deadly punch: a coinfection of the two, creating a third, doubly-infected group not yet on the radar screens of community health organizations. At the front lines of the HCV and HIV/AIDS epidemics are two local nonprofits: Hep-C ALERT and Wel
BOSTON-- French researchers presented new 48-week data from a Phase III clinical trial today. These data demonstrate that emtricitabine (FTC), an investigational once-daily nucleoside reverse transcriptase inhibitor (NRTI), suppresses HIV when taken as part of a once-daily, protease inhibitor (PI)-sparing antiretrovira
BOSTON-- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) reported encouraging new findings from a phase-2 clinical trial of its investigational drug, PRO 542, for treatment of human immunodeficiency virus (HIV) infection. Progenics scientists found that the magnitude of viral load reductions observed in a previously com
DALLAS-- Instead, Inc. has signed an agreement with Rush-Presbyterian-St. Luke s Medical Center, Chicago, under which it has obtained an exclusive worldwide license to develop and sell a microbicide, currently called Acidform, that has shown potential for use as a contraceptive and for the prevention of sexually transm
LOS ANGELES--AIDS Healthcare Foundation (AHF): Online Pharmacy Canadian Drugstore Spearheads Product Boycott Against GlaxoSmithKline after Drug Giant Allegedly Pressured Canadian Drug Wholesalers to Cut off Sales of Life-Saving AIDS Meds & Other Drugs to U.S. Customers AIDS Healthcare Foundation (AHF), the nation s
BOSTON--(BUSINESS WIRE)--Feb. 3, 2003--A new study in the February issue of Harvard Business Review says that it is cost-effective for businesses to provide HIV/AIDS prevention and treatment programs for their employees in countries stricken by the epidemic. Responses that are good for public health-prevention and trea
BETHLEHEM, Pa.--(BUSINESS WIRE)--Feb. 3, 2003--OraSure Technologies, Inc. (Nasdaq:OSUR), the market leader in oral fluid diagnostics, announced that the United States Navy Military Sealift Command has purchased 10,000 OraQuick(R) Rapid HIV-1 Antibody Tests to screen its personnel participating in the smallpox vaccinati
ALAMEDA, Calif.--(BUSINESS WIRE)--Feb. 3, 2003--Calypte Biomedical Corporation (OTCBB:CALY), the developer and marketer of the only two FDA approved HIV-1 antibody tests that can be used on urine samples, as well as an FDA approved serum HIV-1 antibody Western blot supplemental test, commented on President George W. Bu
LOS ANGELES--(BUSINESS WIRE)--Feb. 1, 2003--AIDS Healthcare Foundation: -- Nation s Largest AIDS Organization Questions Difference in Pricing for Central America versus Africa; Challenges Drug Companies to Match African Prices and Follow President Bush s Call for Greater Access in the Developing World-- AIDS Healthcare
BETHLEHEM, Pa.--(BUSINESS WIRE)--Jan. 31, 2003--OraSure Technologies, Inc. (NasdaqNM:OSUR), the market leader in oral fluid diagnostics, announced today that the U.S. Food and Drug Administration ( FDA ), through its Center for Devices and Radiological Health, has approved a waiver under the Clinical Laboratory Improve
LA JOLLA, Calif.--(BUSINESS WIRE)--Jan. 31, 2003--Aethlon Medical Inc. (OTCBB:AEMD) today announced that initial pre-clinical human blood studies of the company s new HCV-Hemopurifier(TM) have documented a consistent ability to remove 58 percent of Hepatitis-C virus (HCV) from infected blood in two hours. The data was
BERNARDSVILLE, N.J.--(BUSINESS WIRE)--Jan. 30, 2003--Millennium Biotechnologies, Inc., a wholly owned subsidiary of Millennium Biotechnologies Group, Inc., today announced that its proprietary product Prosurgex(TM) has been launched in California where it is being reimbursed by Medi-Cal, the state-run Medicaid agency.
MIAMI--(BUSINESS WIRE)--Jan. 30, 2003--IVAX Corporation announced today that it is developing, in collaboration with the Laboratory of Molecular Biology of the National Cancer Institute, a recombinant immunotoxin designed to treat HIV infection by selectively destroying HIV infected cells. This immunotoxin is engineere
LA JOLLA, Calif.--(BUSINESS WIRE)--Jan. 29, 2003--Aethlon Medical Inc. announced that it has been invited to make a presentation at the International Conference on Dialysis V which starts today at the Fontainebleau Hilton Resort in Miami. Aethlon s Chief Scientific Officer, Dr. Richard Tullis, will present data from re
HOUSTON--(BUSINESS WIRE)--Jan. 28, 2003--If passed, it promises to be one of the hardest blows yet to Texas healthcare reform. In an effort to lower budget deficits, this year 13 state Aids Drug Assistance Programs (ADAPs), including Texas, are expected to limit access to HIV medications for thousands of uninsured and
SEATTLE--(BUSINESS WIRE)--Jan. 28, 2003--Kaleidos Pharma, Inc. today announced that the Division of AIDS of the National Institute of Allergy and Infectious Diseases at the National Institutes of Health (NIH) will initiate a second study in SIV-infected rhesus macaque monkeys of Kaleidos proprietary drug, TGF alpha. Th
WASHINGTON, DC, CAPE TOWN and DURBAN, SOUTH AFRICA--(BUSINESS WIRE)--Jan. 28, 2003--AIDS Healthcare Foundation: -- Competition Commission Complaint by AIDS Healthcare Foundation Seeks to Require GSK to Allow Licensing and Manufacturing of Life-Saving AIDS Drugs by Generic Makers -- AHF Announces Action in Durban &
ALAMEDA, Calif.--(BUSINESS WIRE)--Jan. 27, 2003--Calypte Biomedical Corporation, the developer and marketer of the only two FDA approved HIV-1 antibody tests that can be used on urine samples, as well as an FDA approved serum HIV-1 antibody Western blot supplemental test, today announced that a recent study from The Jo
NEW YORK--(BUSINESS WIRE)--Jan. 15, 2003--Innovative Technology Acquisition Corporation (OTCBB:ITAQ) has announced that its wholly-owned subsidiary, BioSource Therapeutics, Inc., is targeting Nutraplete, its proprietary, multi-component nutritional supplement for immune-compromised individuals, in three key states: New
CARLSBAD, Calif.--(BUSINESS WIRE)--Jan. 9, 2003--The Immune Response Corporation (Nasdaq:IMNR) announced today the appointment of John N. Bonfiglio, Ph.D. as the Company s new chief executive officer. Bonfiglio, who brings biotechnology, drug development and licensing experience to the company, is charged with spearhea
SEATTLE--(BUSINESS WIRE)--Jan. 9, 2003--Kaleidos Pharma, Inc. (KPI) today announced that the company has been issued United States Patent Number 6,486,122. This patent covers the use of certain cytokines, including TGF alpha, in treating chronic wasting disease associated with cancer, AIDS and other diseases. Chronic w
ALAMEDA, Calif.--(BUSINESS WIRE)--Jan. 8, 2003--Calypte Biomedical Corporation (OTCBB:CALY), the developer and marketer of the only two FDA-approved HIV-1 antibody tests that can be used on urine samples, today announced receipt of U.S. Food and Drug Administration (FDA) approval to eliminate the lot release testing re
BETHLEHEM, Pa.--(BUSINESS WIRE)--Jan. 7, 2003--OraSure Technologies, Inc. (Nasdaq:OSUR), the market leader in oral fluid diagnostics, announced today that it has shipped more than 50,000 OraQuick(R) Rapid HIV-1 Antibody Tests to Abbott Laboratories . This order was completed in late December 2002, and represents the fi
SEATTLE--(BUSINESS WIRE)--Jan. 7, 2003--Today, Viacom and the Henry J. Kaiser Family Foundation are launching a groundbreaking national HIV/AIDS advertising campaign of which a portion of the television and outdoor campaign was created and produced by DDB Bass & Howes. To date, this is the largest public service ad
This information is designed to support, not replace, the relationship that exists between you and your doctor.